Home › Compound Library › Selank
Cognitive and stress
Selank: An Anxiolytic Without the Sedation, and Where Its Evidence Comes From
The short answer
Selank is a seven-amino-acid peptide built from tuftsin, a fragment of an antibody. It is registered in Russia as a treatment for anxiety, where the appeal is that it damps anxiety without the sedation, dependence or withdrawal that come with benzodiazepines.
Questions people ask about Selank
Selank at a glance
| Also called | TP-7; tuftsin analogue; N-acetyl selank is the acetylated version |
|---|---|
| What it is | A synthetic heptapeptide: the immune fragment tuftsin with a Pro-Gly-Pro tail for stability |
| Acts on | GABAergic and serotonergic signalling; BDNF expression; enkephalin breakdown |
| Main system | Brain: anxiety, stress resilience, attention under load |
| Evidence level | Registered and used clinically in Russia; the published record elsewhere is largely animal work |
| FDA status (Oct 2026) | Not approved. It was not among the peptides the July 2026 advisory committee recommended |
| In sport | Not named on the 2026 WADA prohibited list |
What is selank?
Tuftsin is a four-amino-acid fragment of an antibody, with a role in immune signalling. Russian researchers attached the same three-amino-acid tail used for semax, Pro-Gly-Pro, to keep it from being broken down immediately. The result was selank: seven amino acids, aimed at anxiety.
Like semax it is given as a nasal spray in clinical use, and like semax it came out of the Institute of Molecular Genetics at the Russian Academy of Sciences.
The claim that made it interesting is specific: anxiolytic effect without sedation, without cognitive dulling, and without the dependence and withdrawal that define the benzodiazepine class.
The Cognitive Advantage profiles it at pp. 133–140 and Targeted Peptide Systems at pp. 176–179.
How does selank work?
The mechanism is less settled than semax’s, and the honest summary is that several threads have been described without one of them clearly dominating:
- GABA signalling. Research describes effects on the GABAergic system, which is the system benzodiazepines act on directly. Selank appears to influence it without binding the same site, which would explain the absence of sedation and dependence.
- Serotonin and monoamines. It also acts on serotonergic signalling, which is relevant to both anxiety and mood.
- Enkephalins. Selank slows the breakdown of enkephalins, the body’s own short-acting opioid signals, which is part of the proposed anti-anxiety mechanism.
- BDNF. As with semax, effects on brain-derived neurotrophic factor have been described.
A 2020 paper in Doklady Biological Sciences took a connectomic approach to mapping what selank and semax each do, which is a useful illustration of how the two are studied as a pair (reference 1).
The Cognitive Advantage (pp. 64–68) places both among the compounds that support the brain’s own regulation rather than stimulating it.
What does the research show?
The clinical use is real. Selank is a registered medicine in Russia, dispensed through pharmacies there and in Ukraine, used for generalised anxiety, and that registration rests on trials run within the programme that developed it.
The internationally indexed record fills in the mechanism, and it is consistent: studies report reduced anxiety-like behaviour, protection against stress-induced changes, attenuation of aversive signs during morphine withdrawal in rats (reference 2), and protection against ethanol-induced memory impairment (reference 3).
Where the evidence stands. The same shape as semax: decades of registered clinical use, a literature published largely in Russian, and a mechanistic record that is consistent across several threads. A clinical history on one side and a described mechanism on the other is a stronger position than most compounds discussed as research peptides occupy.
Side effects and cautions
The safety record from Russian clinical use is quiet, and the absence of the benzodiazepine problems, sedation, dependence and withdrawal, is the specific claim made for it. Nasal irritation from the spray is the most commonly reported effect.
What that record does not cover is continuous use outside a clinical setting, and the long-term safety data a Western approval process generates does not exist yet. Both are worth factoring in when deciding how long to use anything.
The caution that matters most here is not about the molecule. Anxiety disorders are treatable, and treatment works: therapy and approved medicines both have substantial evidence behind them. If anxiety is affecting your life, that deserves a proper assessment, and selank is something to raise with a clinician as a possible addition rather than a replacement for one.
Product quality is the other practical risk, as with anything sold for research use.
Is selank legal or FDA approved?
Not FDA approved. There is no approved selank product in the United States, and it was not among the six peptides the FDA advisory committee recommended for compounding in July 2026 (references 4, 5). Semax was; selank was not, which is the same committee drawing a line between two compounds from the same research tradition.
It is a registered medicine in Russia, which is the source of the clinical experience and has no bearing on its US status.
Sport: selank is not named on the 2026 WADA prohibited list. Check with your governing body, since lists are updated annually.
Selank vs semax, and where it sits
These two are constantly confused, and they are genuinely siblings: same research tradition, same stabilising tail, same nasal route, different targets.
- vs semax: semax is built from an ACTH fragment and aimed at attention, recovery and neuroprotection. Selank is built from tuftsin and aimed at anxiety and stress. Semax was recommended for compounding in July 2026; selank was not.
- vs benzodiazepines: the comparison selank exists to make. Benzodiazepines are fast, effective and well evidenced, and they carry sedation, tolerance, dependence and withdrawal. Selank is aiming at the effect without the burden, with a much younger evidence base. That is the trade-off being weighed, not a verdict.
- vs epitalon: the third compound from this tradition in our library, aimed at an entirely different system.
The Cognitive Advantage (pp. 64–68) is where the book sets out how it chooses between cognitive compounds rather than stacking them.
Risk, benefit, and the conversation this page is for
Selank arrived in the clinic the same way semax did. It is a registered medicine in Russia, dispensed through pharmacies there and in Ukraine, prescribed for anxiety on the strength of trials run within that programme. The internationally indexed record fills in the mechanism and points the same way. A registered clinical history on one side and a described mechanism on the other is a stronger position than most compounds discussed as research peptides occupy.
The regulatory picture is moving, and it is moving one compound at a time. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. The same committee has turned peptides down and still does: ipamorelin and CJC-1295 sit in Category 2, barred from compounding. The distinction is the useful part. Each compound is being read on its own risk record rather than lumped under one verdict called unapproved.
The clinicians working with these compounds are not fringe, and their reasoning is comparative rather than enthusiastic. The approved options for chronic inflammation and slow-healing tissue carry burdens that are thoroughly documented: long-term anti-inflammatories on the gut and kidneys, repeated corticosteroid injections on connective tissue, glucose control and bone. Weighed against that, a compound with a quiet toxicology record and an incomplete efficacy record is a reasonable thing to discuss. It is not a reasonable thing to promise, and that is the line this page tries to hold.
Which is the point of the series. Nothing here is a recommendation to use selank. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
Selank: frequently asked questions
What is selank?
A seven-amino-acid peptide built from tuftsin, an antibody fragment, with a Pro-Gly-Pro tail added for stability. It is registered in Russia as a treatment for anxiety.
What is selank used for?
In Russia, where it is a registered medicine, for generalised anxiety. Elsewhere it is discussed for stress resilience and attention under pressure, which extrapolates from that use and from animal work.
Is selank FDA approved?
No. There is no approved product in the US, and it was not among the six peptides the July 2026 advisory committee recommended for compounding.
Selank vs semax: what is the difference?
Same research tradition and same stabilising tail, different targets. Semax comes from an ACTH fragment and aims at attention and recovery; selank comes from tuftsin and aims at anxiety.
Does selank cause sedation?
The specific claim made for it is an anxiolytic effect without sedation, cognitive dulling, dependence or withdrawal. That is the basis on which it has been prescribed in Russia for years.
How does selank work?
Several threads at once: effects on GABAergic and serotonergic signalling, slowed breakdown of the body’s own enkephalins, and effects on BDNF. It acts on more than one of the systems involved in the stress response.
What are selank’s side effects?
Nasal irritation from the spray is the most commonly reported. The record from Russian clinical use is quiet; long-term systematic safety data has not been generated.
Is selank banned in sport?
It is not named on the 2026 WADA prohibited list. Check with your sport’s governing body, as lists change each year.
Where Selank appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how Selank fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
The Cognitive Advantage
Profile, Category 1 cognitive compounds · pp. 133-140
About the bookLook Inside
Books marked Look Inside include these exact pages in their free preview.
Related compounds
See how Selank fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Functional connectomic approach to studying selank and semax effects. Dokl Biol Sci. 2020;490(1):9–11. View source
- Selank, a peptide analog of tuftsin, attenuates aversive signs of morphine withdrawal in rats. Bull Exp Biol Med. 2022;173(6):730–733. View source
- Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating inflammatory reactions. Bull Exp Biol Med. 2019;167(5):641–644. View source
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Selank is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.